DBV Technologies Logo

DBV Technologies

Developing non-invasive skin patch immunotherapy for severe food allergies like peanut and milk.

DBV | PA

Overview

Corporate Details

ISIN(s):
FR0010417345 (+3 more)
LEI:
969500PVBQFWQKVDMD80
Country:
France
Address:
107 AVENUE DE LA REPUBLIQUE, 92320 CHATILLON
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies. The company's core technology is the proprietary Viaskin™ platform, an investigational form of epicutaneous immunotherapy (EPIT). This non-invasive patch technology is designed to deliver biologically active compounds, such as allergens, to the immune cells of the skin, thereby re-educating the immune system. DBV's development pipeline includes product candidates for common food allergies, with its lead program, Viaskin Peanut (DBV712), in late-stage clinical trials for peanut-allergic patients. Another key program is Viaskin Milk (DBV135) for milk allergies. Founded by pediatricians, the company is dedicated to improving the lives of patients with potentially life-threatening food allergies.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 05:50
ISS
DBV Technologies annonce la dernière visite du dernier patient dans l'essai cli…
French 219.7 KB
2025-11-12 05:50
ISS
DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clin…
English 220.0 KB
2025-10-30 21:30
Board/Management Information
DBV Technologies annonce la nomination de Philina Lee, Ph.D. au sein de son Con…
French 197.8 KB
2025-10-30 21:30
Board/Management Information
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Direct…
English 194.0 KB
2025-10-28 21:25
Earnings Release
DBV Technologies Reports Third Quarter 2025 Financial Results
English 272.3 KB
2025-10-28 21:25
Earnings Release
DBV Technologies publie ses résultats financiers du troisième trimestre 2025
French 274.7 KB
2025-10-14 15:44
Major Shareholding Notification
Franchissement de seuils
French 266.6 KB
2025-06-20 12:46
Major Shareholding Notification
Franchissement de seuils
French 124.2 KB
2025-06-17 16:58
Major Shareholding Notification
Franchissement de seuils
French 107.2 KB
2025-06-12 22:05
Earnings Release
DBV Technologies to Participate in Upcoming EAACI Congress 2025
English 275.8 KB
2025-06-12 22:05
Regulatory News Service
DBV Technologies participera au prochain congrès EAACI 2025
French 269.7 KB
2025-06-11 22:30
Post-Annual General Meeting Information
DBV Technologies annonce les résultats de son Assemblée Générale Mixte 2025
French 179.9 KB
2025-06-11 22:30
Declaration of Voting Results & Voting Rights Announcements
DBV Technologies Announces the Voting Results of its 2025 Combined General Meet…
English 179.7 KB
2025-06-04 22:32
Declaration of Voting Results & Voting Rights Announcements
Information Regarding the Total Number of Voting Rights and Total Number of Sha…
English 169.6 KB
2025-06-04 22:32
Declaration of Voting Results & Voting Rights Announcements
Information relative au nombre total des droits de vote et d’actions composant…
French 150.3 KB

Automate Your Workflow. Get a real-time feed of all DBV Technologies filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for DBV Technologies

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for DBV Technologies via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-06-09 N/A Other Other 2,483,161 7,449,483.00 EUR

Peer Companies

1NKEMIA Logo
A tech group providing R&D, services, training, and investment for life sciences industries.
Spain
IKM
AI-powered genome sequencing and reanalysis to diagnose rare diseases globally.
South Korea
394800
4D Molecular Therapeutics, Inc. Logo
Developing targeted AAV genetic medicines for large market eye, lung, and heart diseases.
United States of America
FDMT
AbCellera Biologics Inc. Logo
An AI-powered platform that discovers and develops antibody therapeutics for pharma partners.
United States of America
ABCL
Develops antibody therapeutics and CAR-T for oncology and provides CRO services.
South Korea
174900
Clinical-stage biopharma developing therapeutics for oncology & viral infectious diseases.
South Korea
203400
Abivax S.A. Logo
Biotech developing oral drugs for chronic inflammatory diseases like colitis and Crohn's.
United States of America
ABVX
ABL Bio Inc. Logo
Develops bispecific antibody therapies for oncology and neurodegenerative diseases.
South Korea
298380
Absci Corp Logo
A generative AI drug creation platform for designing and optimizing biologic therapeutics.
United States of America
ABSI
ABVC BIOPHARMA, INC. Logo
Develops plant-based drugs and medical devices for CNS, oncology, and ophthalmic disorders.
United States of America
ABVC

Talk to a Data Expert

Have a question? We'll get back to you promptly.